Literature DB >> 22934675

The role of telomere biology in cancer.

Lifeng Xu1, Shang Li, Bradley A Stohr.   

Abstract

Telomere biology plays a critical and complex role in the initiation and progression of cancer. Although telomere dysfunction resulting from replicative attrition constrains tumor growth by engaging DNA-damage signaling pathways, it can also promote tumorigenesis by causing oncogenic chromosomal rearrangements. Expression of the telomerase enzyme enables telomere-length homeostasis and allows tumor cells to escape the antiproliferative barrier posed by short telomeres. Telomeres and telomerase also function independently of one another. Recent work has suggested that telomerase promotes cell growth through pathways unrelated to telomere maintenance, and a subset of tumors elongate telomeres through telomerase-independent mechanisms. In an effort to exploit the integral link between telomere biology and cancer growth, investigators have developed several telomerase-based therapeutic strategies, which are currently in clinical trials. Here, we broadly review the state of the field with a particular focus on recent developments of interest.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22934675     DOI: 10.1146/annurev-pathol-020712-164030

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  55 in total

1.  Association of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.

Authors:  Jonathan R George; Ying C Henderson; Michelle D Williams; Dianna B Roberts; Hu Hei; Stephen Y Lai; Gary L Clayman
Journal:  J Clin Endocrinol Metab       Date:  2015-10-13       Impact factor: 5.958

Review 2.  Telomere biology: Rationale for diagnostics and therapeutics in cancer.

Authors:  Philippe Rousseau; Chantal Autexier
Journal:  RNA Biol       Date:  2015-08-20       Impact factor: 4.652

Review 3.  NRF2 and the Hallmarks of Cancer.

Authors:  Montserrat Rojo de la Vega; Eli Chapman; Donna D Zhang
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

4.  TERT promoter mutations are rare in bone and soft tissue sarcomas of Japanese patients.

Authors:  Tsuyoshi Saito; Keisuke Akaike; Aiko Kurisaki-Arakawa; Midori Toda-Ishii; Kenta Mukaihara; Yoshiyuki Suehara; Tatsuya Takagi; Kazuo Kaneko; Takashi Yao
Journal:  Mol Clin Oncol       Date:  2015-11-09

Review 5.  DAMPs, ageing, and cancer: The 'DAMP Hypothesis'.

Authors:  Jin Huang; Yangchun Xie; Xiaofang Sun; Herbert J Zeh; Rui Kang; Michael T Lotze; Daolin Tang
Journal:  Ageing Res Rev       Date:  2014-10-30       Impact factor: 10.895

6.  Aberrant expression of ETS1 and ETS2 proteins in cancer.

Authors:  Elizabeth A Fry; Kazushi Inoue
Journal:  Cancer Rep Rev       Date:  2018-04-23

7.  Soluble purified recombinant C2ORF40 protein inhibits tumor cell growth in vivo by decreasing telomerase activity in esophageal squamous cell carcinoma.

Authors:  Linwei Li; Xiaoyan Li; Wenyu Wang; Tianhui Gao; Yun Zhou; Shixin Lu
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

8.  Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.

Authors:  Ludger Klewes; Rhea Vallente; Eric Dupas; Carolin Brand; Dietrich Grün; Amanda Guffei; Chirawadee Sathitruangsak; Julius A Awe; Alexandra Kuzyk; Daniel Lichtensztejn; Pille Tammur; Tiiu Ilus; Anu Tamm; Mari Punab; Morel Rubinger; Adebayo Olujohungbe; Sabine Mai
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

9.  TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.

Authors:  Ze-Lin Sun; Aden Ka-Yin Chan; Ling-Chao Chen; Chao Tang; Zhen-Yu Zhang; Xiao-Jie Ding; Yang Wang; Chong-Ran Sun; Ho-Keung Ng; Yu Yao; Liang-Fu Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Association between leukocyte telomere length and glioma risk: a case-control study.

Authors:  Shaolong Wang; Yibing Chen; Falin Qu; Shiming He; Xiaojun Huang; Hequn Jiang; Tianbo Jin; Shaogui Wan; Jinliang Xing
Journal:  Neuro Oncol       Date:  2013-12-22       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.